Review Article

Pneumococcal proteins and the pathogenesis of disease caused by *Streptococcus pneumoniae*

GRAHAM J. BOULNOIS*

Department of Microbiology, Medical Sciences Building, University of Leicester, Leicester LE1 9HN, UK

Introduction

*Streptococcus pneumoniae* is an important agent of disease in man at the extremes of age and in individuals with underlying debilitating conditions. It is responsible for the majority of cases of community-acquired pneumonia, an important cause of septicaemia, one of the three most common pathogens in bacterial meningitis and the most prevalent agent in otitis media (Roberts, 1985). The precise incidence of each of these infections is not known because of problems in diagnosis (particularly with respect to pneumonia and otitis media) and inadequate reporting of cases. However, Austrian (1982b), having reviewed a number of studies, concluded that in the USA there are 2–5 cases of pneumonia per 1000 population per annum, equating to between 440000 and $1 \times 10^6$ cases each year. Despite antibiotic therapy the case fatality rate is about 5–7%, making pneumonia one of the major causes of morbidity and mortality in the developed world. In the same study, Austrian estimated that the attack rate for septicaemia was between 25 and 50 per 100000 population per annum, with a case fatality rate of between 17 and 24%. Most, but not all, of these cases were associated with lower respiratory tract infections. In an attempt to focus attention on the desirability of developing an effective vaccine to protect against pneumococcal infection, this situation was likened, in terms of incidence and mortality, to that of poliomyelitis prior to the introduction of the vaccine. The incidence of pneumococcal meningitis is estimated to be about 0.5 per 100000 population per annum (Austrian, 1982b). It seems likely that similar attack and fatality rates are found in Europe. As may be expected, pneumococcal infection in the Third world poses enormous problems, with attack rates of over 10 per 1000 population per annum (Greenwood, 1987).

Both bacteraemia and meningitis can be associated with pneumonia. In untreated infections, the co-incidence of pneumonia and bacteraemia (about 30% of cases), and pneumonia and meningitis (about 2% of cases at post mortem), varies with serotype and the population studied (Heffron, 1939). In one study, more than 50% of fatal cases of untreated pneumonia were associated with bacteraemia and in some groups 10–5% of fatal pneumonias were accompanied by meningitis (Heffron, 1939).

Pneumococcal carriage and disease

Although the pneumococcus is an important cause of disease, its normal ecological niche is the nasopharynx of man and occasionally animals. It is likely that the entire human population is colonized by the pneumococcus at one time or another, and that at a given time up to 60% of individuals may be carriers (Austrian, 1986). Simultaneous carriage of more than one serotype is well documented, and this can be reflected in mixed infections (Austrian *et al.*, 1977). In general, the rate of disease within a population depends on the frequency with which invasive serotypes are carried in the nasopharynx (Riley & Douglas, 1982). However, in certain populations some serotypes are rarely carried but are frequently isolated from cases. These serotypes may be considered as particularly virulent, with the carrier state being at best a transient state. Conversely, some serotypes are frequently carried yet rarely cause disease and some serotypes show a propensity for persistence in healthy carriers. Interestingly, infection is more likely to result following the recent acquisition of a given
pneumococcal strain rather than an extended period of carriage. Nasopharyngeal carriage of pneumococci by man is very often accompanied by the development of protection to infection by the same serotype. Carriage rates are inversely related to age and the levels of antcapsular antibody and thus it is clear that the immune status of the host is an important determinant of the prevalence and longevity of carriage (Gwaltney et al., 1975). A priori it is reasonable to suppose that pneumococcal factors also influence carriage and there is circumstantial evidence to support this suggestion, although very little is known of the pneumococcal carrier state in terms of the host-microbe interaction.

For many bacteria which colonize the mucosal surfaces the production of specific factors which are thought to mediate attachment of bacteria to epithelial cells is commonplace. It has been suggested (Andersson et al., 1983) that pneumococci adhere to cells via an interaction with GlcNAcβ1-3Gal. However, another study (Krivan et al., 1988) indicated that pneumococci bind to GalNAcβ1-4Gal and in this regard resembled other bacteria which exhibit a tropism for the upper respiratory tract. GalNAcβ1-4Gal is found in a number of glycosphingolipids and one of these, asialo-GM1, is found in substantial amounts in human lung tissue. The nature of the pneumococcal adhesin is not clear, although a protein-like molecule has been described which acts as a sandwich to bridge a pneumococcal cell wall component and the target receptor on epithelial cells (Andersson et al., 1988). The same authors point out the similarities between the sandwich adhesin and the competence factor of the pneumococcus, which is involved in natural transformation. Pneumococcal isolates from cases of otitis media were found to be more proficient at attachment to human pharyngeal epithelial cells than those from septicaemia and meningitis (Andersson et al., 1981). This may indicate that expression of adhesive capacity is modulated by the in vitro environment.

Other pneumococcal factors which may be involved in colonization include neuraminidase. This enzyme cleaves sialic acid from glycolipids and gangliosides and has been suggested to expose receptors for pneumococcal attachment (Krivan et al., 1988). This may explain why attachment of S. pneumoniae to respiratory epithelial cells is enhanced following infection with the neuraminidase-producing influenza virus (Plotkowski et al., 1986) and perhaps, in part, account for the prevalence of pneumococcal disease following influenza infection. Pneumococci also produce an IgA1-specific protease (see below) which may act to compromise host defence at the mucosal surface (Kilian & Reinholdt, 1986). Similarly the properties of pneumolysin described below indicate that it might also serve to abrogate host defence in the nasopharynx and facilitate colonization. Although many of these factors have been considered as virulence factors (see below), it is not unreasonable to suggest that their primary role is in promoting carriage and that their virulence potential is only manifest when bacteria gain access to normally restricted sites.

**Pathogenesis of pneumococcal infection**

The processes involved in the translocation of pneumococci from the nasopharynx to other sites, including the lung, are poorly understood and probably multifactorial (Busse, 1991, Johnston, 1991).

Given the prevalence of the carrier state and the relative rarity of pneumococcal infection it is apparent that at any one time most individuals are protected from pneumococcal disease. It has been generally accepted for many years that pneumonia results from the inhalation of pneumococci from the upper respiratory tract, although in some animal models a blood-borne route of dissemination from the upper respiratory tract has been described (Rake, 1936). A multitude of specific and non-specific defences protect the lower respiratory tract. Important non-specific mechanisms include filtration, cough reflexes, secretions and mucociliary transport (Busse, 1991). Many events can compromise these defences, including sleep and agents that affect the level of consciousness (anaesthesia, drug and alcohol abuse).

Viral infection of the respiratory tract also disrupts non-specific defences of the lung, and the association between influenza and pneumococcal pneumonia is well documented. Humoral and cellular components of host defence are also important in the respiratory tract (Busse, 1991). Antibody and complement components which are particularly prevalent in the alveolar lining fluid act as opsonins to facilitate phagocytosis. The resident alveolar macrophage is likely to be a key cell in this regard, at least initially, although complement cleavage products as well as macrophage and bacterial products also act to recruit polymorphonuclear leucocytes (PMNLs). Once ingested, pneumococci are rapidly killed by phagocytic cells (Johnston, 1991).

It will be evident that a myriad of cells and molecules of the immune system cooperate to protect the lung, and that the interplay between host defences and pneumococcal factors is complex. Failure of these defences to clear inhaled bacteria from the lower respiratory tract is a balance between the effectiveness of host defences, the size and nature of the inoculum and the virulence potential of the pneumococcus in question. Pneumococcal multiplication in the lower respiratory tract gives rise to the classical features of lobar pneumonia, which proceeds in an overlapping series of steps (Johnston,
Initially, there is alveolar engorge-
ment associated with oedema and bacteria in the alveoli. Red hepatization follows PMNL infiltration and the appearance of blood-tinged fluid: bacteria, fibrin and erythrocytes abound in the alveoli. Grey hepatization is apparent as the alveoli become progressively blocked by fibrin and PMNLs, and bacteria are cleared. Resolution accompanies the influx of macrophages and following recovery there is little evidence of residual tissue damage. A variety of pneumococcal factors may play a key role in the induction of the inflammatory response, and it has been shown that cell wall components can induce pulmonary inflammation (Tuomanen et al., 1987) and pneumolysin (see below) alone can produce all the salient histological features of pneumonia in experimental animals.

Bacteraemia/septicaemia frequently accompanies lower respiratory tract infection but septicaemia in the absence of a primary focus of infection can occur. The site at which pneumococci gain access to the blood-
stream and the mechanism by which this occurs is not clear, although several routes are possible which need not be mutually exclusive. In some studies, pneumococci are found in the blood only a few minutes after intranasal challenge of mice and might have invaded via the nasopharyngeal mucosa (Rake, 1936). Invasion from the lower respiratory tract, perhaps involving transport in the lymphatics via the hilar nodes, is also possible since pneumococci were also found in alveoli shortly after challenge. Similar experiments in rabbits (Schulz et al., 1938) indicated that bacteraemia was preceded by the appearance of pneumococci in the cervical lymphatics. In intravenously challenged rabbits, pneumococci can cross both vascular and lymphatic endothelium and the lymphatics can serve as a reservoir of replicating pneumococci even in the presence of anti-pneumococcal antibody (Field et al., 1987). Additionally, pneumococci in the subarachnoid space (see below) may also gain access to the cerebral venous system (Austrian, 1982b).

Both the liver and the spleen in conjunction with antibody play an important role in the clearance of pneumococci from the bloodstream (Austrian, 1982b). The spleen is thought to be important in the synthesis of antibody, in bacterial clearance in the non-immune host and to play a role in alternative pathway activation (Wara, 1982). Hence it is not surprising that the splenectomized individual is at particular risk from pneumococcal infection (Wara, 1982). The acute-phase reactant C-reactive protein (CRP) may also facilitate elimination of pneumococci from the blood (Briles et al., 1989; Horowitz et al., 1987). CRP is an acute-phase protein, first identified by its ability to bind to the C-polysaccharide from the pneumococcal cell wall. Following binding to its ligand, CRP activates the classical pathway of complement via direct binding of the C1q component of complement to ligand-fixed CRP (Volanakis & Kaplan, 1974). In this regard CRP acts as a primitive antibody and as such may be an important component of non-specific defence against bacterial infection in the preimmune phase of infection. Indeed, passive immunisation of mice with human CRP was found to protect mice from pneumococcal challenge (Mold et al., 1981; Yother et al., 1982).

The presence of pneumococci in the blood of man and animals with pneumonia correlates with poor prognosis although the reasons why infected individuals die from the infection is still not known. The 'toxic' nature of pneumococcal infections has been highlighted on many occasions (Johnston, 1991), although the specific nature of the pneumococcal component responsible for the observed toxicity has not been definitively identified. The polysaccharide capsule, although required for in vivo multiplication, is not toxic and thus other pneumococcal factors must be important (either directly or indirectly) in promoting damage. The elimination of pneumococci from infected individuals using antibiotics often fails to alleviate the fatal outcome of infection. Dick & Gemmell (1971) were able to reproduce this effect in infected mice. These authors interpret this to indicate that a pneumo-
coccal toxin, perhaps pneumolysin (see below), plays a part in the fatal outcome of the infection. The observa-
tion that pneumolysin antibodies delay the fatal outcome of pneumococcal infection in mice (Paton et al., 1983) might lend credence to this suggestion. Alternatively, it is possible that the bacterial load is sufficiently high that the induction of pneumococcal lysis by the antibiotic releases a variety of pneumococcal products which induce irreversible shock. Elevated serum levels of tumour necrosis factor (TNF) (Nohynk et al., 1991) and raised levels of interleukin-1 in broncho-alveolar wash-
ings (Wilmott et al., 1990) have been observed in children with acute lower respiratory tract infections. Interestingly, pneumococcal cell wall components have been reported to stimulate interleukin-1 but not TNF production from human monocytes (Riesenfeld-orn et al., 1989). The patterns of cytokine production induced by the action of pneumolysin on immune cells is not known.

The mechanisms and route by which pneumococci gain access to the meninges and cause meningitis is not clear. Haematogenous spread is one possibility, although meningitis rarely ensues following intravenous inoculation of animals with pneumococci (Moxon, 1982). It was observed that pneumococci rapidly appeared in the subarachnoid space following intranasal challenge of mice and it was speculated that they did so via the olfactory mucosa (Rake, 1937), perhaps involving the perineural spaces around olfactory neurons (Moxon,
Pneumococcal neuraminidase has been implicated in the pathogenesis of meningitis (see below).

**Pneumococcal virulence factors**

The pneumococcus produces a number of products having properties consistent with a role in promotion and maintenance of the carrier state and the pathogenesis of disease. However only in the cases of the capsular polysaccharide (Austrian, 1982a), pneumococcal surface protein A, and the toxin pneumolysin (Berry et al., 1989a) is there clear evidence that they are virulence factors. Autolysin may also contribute to the disease process (see below) although this may be an indirect effect consequent on autolysin-mediated release of pneumococcal cell wall and other factors (Berry et al., 1989a).

**Capsule**

The capsule of the pneumococcus plays a key role in virulence since non-capsulate derivatives of previously virulent pneumococci show a reduction in virulence of several orders of magnitude and the capsule acts to restrict opsonophagocytosis of the bacterium (Austrian, several orders of magnitude and the capsule acts to virulence since non-capsulate derivatives of previously virulent pneumococci show a reduction in virulence of several orders of magnitude and the capsule acts to restrict opsonophagocytosis of the bacterium (Austrian, 1982b). Some 83 capsular polysaccharides have been described on the surface of the pneumococcus and these form the basis of the serological typing of *S. pneumoniae*. The association of capsular type and disease is well documented, as is the importance of anticapsular antibodies in protection against pneumococcal infection. These observations have led to the introduction of a 23-valent polysaccharide vaccine against pneumococcal infection; whilst this has proved effective in protecting at-risk adults it is of questionable efficacy in those of the population most at risk from the disease (van Dam et al., 1990). This reflects the fact that capsular polysaccharides are often weak immunogens, eliciting poor antibody responses, and because of the T-cell independence of the response fail to induce memory.

**Surface protein**

Pneumococcal surface protein A (PspA) is present on the surface of many, if not all, clinical isolates of the pneumococcus (Crain et al., 1990) and has a postulated structure which is unique, although some similarities to other surface proteins in Gram-positive bacteria (e.g. M proteins in group A streptococci) are evident (Yother et al., 1991). Passive immunization with monoclonal antibodies raised against PspA can protect mice against intravenous challenge with certain pneumococcal strains (Briles et al., 1989; McDaniel et al., 1984, 1986). Despite the extensive serological variation in PspA, recombinant PspA from one pneumococcal serotype was shown to confer protection in mice to challenge with different pneumococcal serotypes (McDaniel et al., 1991). The *pspA* gene has been inactivated in a number of virulent pneumococci (McDaniel et al., 1987), resulting in an attenuation of virulence, and in some cases the strains were rendered avirulent (Briles et al., 1988). During the first hour following challenge these *PspA*− pneumococci were more rapidly cleared from mice than their wild-type parents, although after this time there was no obvious difference in clearance or growth rates. Whilst all animals challenged with these mutant pneumococci died from the infection, they did so later than those infected with the wild-type strain (Briles et al., 1988). In this regard the phenotype of the *PspA*− and pneumolysin-negative pneumococci (see below) were similar.

**Neuraminidase**

All pneumococcal isolates produce neuraminidase (Kelly et al., 1967) and although this enzyme may facilitate pneumococcal colonization (see above), it has also been implicated in the pathogenesis of meningitis since intracerebral inoculation of the enzyme in mice induces neurological signs (Kelly & Greiff, 1970). However, these experiments involved only crude preparations of the enzyme and contamination of these preparations with pneumococcal cell wall material would have produced the same result since cell wall components alone have been shown to induce meningeal inflammation (Tuomanen et al., 1985). Nevertheless the observation that immunization of mice with purified neuraminidase conferred limited protection against challenge with virulent pneumococci may indicate that neuraminidase is a pneumococcal virulence factor (Lock et al., 1988).

The number of neuraminidases produced by the pneumococcus has been the subject of controversy. There are reports of several pneumococcal neuraminidase isoenzymes (Tanenbaum et al., 1970; Tanenbaum & Sun, 1971) or the existence of a single neuraminidase which is highly prone to proteolytic degradation (Berry et al., 1988). Recently the genes for two pneumococcal neuraminidases have been cloned (Berry et al., 1988; Camara et al., 1991) and shown to be distinct, and both genes were found in individual pneumococcal isolates of different serotypes (Camara et al., 1991). The relationship between the products of these genes in terms of structure and substrate specificity is not clear and an understanding of these points is clearly important if the role (if any) of neuraminidase in pneumococcal disease is to be elucidated. In an attempt to ascertain the role neuraminidases play in disease we are currently isolating neuraminidase-negative mutants of the pneumococcus.
**Hyaluronidase**

Pneumococci and other streptococci produce hyaluronidase (Humphrey, 1948), an enzyme which depolymerizes hyaluronic acid. The degradation of this important component of the extracellular matrix has been postulated to contribute to the spread of certain streptococci through tissue and it is tempting to hypothesize that the enzyme might contribute to the invasive potential of the pneumococcus. We have recently cloned the gene for pneumococcal hyaluronidase (Boulnois et al., 1991b; A. Shepherd and others, unpublished data) as a first step towards the testing of this hypothesis.

**Pneumolysin**

Pneumolysin is produced by all isolates of the pneumococcus, and the cloning and sequencing of two pneumolysin genes from different serotypes obtained from disparate geographical regions and isolated several decades apart revealed that the proteins differed by only a single amino acid (Mitchell et al., 1990a).

There is good evidence to indicate that pneumolysin is produced during natural infections of man and experimental infections in animals. Antibody titres against pneumolysin have been reported to increase during pneumococcal infection of man (Jalonen et al., 1989; Kanclerski et al., 1988), indicating that the toxin is produced in vivo. In addition, in preliminary experiments, we have been able to detect pneumolysin directly in lung, spleen and liver tissue taken from mice challenged intranasally with pneumococci (T. J. Mitchell and others, unpublished data).

Several lines of evidence indicate that pneumolysin contributes directly to the virulence potential of the pneumococcus. Immunization of mice with native (Paton et al., 1983) and recombinant (Paton et al., 1991) pneumolysin conferred limited protection against an intranasal challenge with virulent pneumococci in a serotype-independent fashion. Although the majority of immunized animals eventually succumbed to the infection, they survived longer than their unimmunized counterparts. Interestingly, when animals immunized with pneumolysin inactivated by site-directed mutagenesis were challenged via the intraperitoneal route, the majority of them survived (Paton et al., 1991). A pneumolysin-negative pneumococcus, generated by insertion-duplication mutagenesis, had reduced virulence for mice and was more rapidly cleared from the bloodstream than the wild-type strain (Berry et al., 1989b). As observed with PspA− pneumococci, mice infected with pneumolysin-negative mutants died much later than the equivalent animals infected with the isogenic wild-type parent. This delay in the fatal outcome of the infection was similar to that observed with the pneumolysin-immunized animals (see above). Thus pneumolysin might be another pneumococcal factor which facilitates in vivo multiplication, and the toxin’s ability to interfere with phagocyte and immune cell function may be important in this regard (see below).

However, the effects of pneumolysin on host tissue are likely to be diverse given that all mammalian cells are, to a greater or lesser extent, susceptible to the toxin. For example, pneumolysin inhibits the beating of cilia on human respiratory tract epithelium (Feldman et al., 1990; Steinfort et al., 1989) and, since beating of cilia is an important facet of the non-specific defences of the respiratory tract, this may promote appearance of pneumococci in the lower respiratory tract.

Pneumolysin belongs to a family of toxins known as the thiol-activated toxins, because they lose activity on oxidation but regain full activity following addition of reducing agents (Smyth & Duncan, 1978). Thiol-activated toxins are produced by four genera of Gram-positive bacteria and have an assumed common mode of action on mammalian cells. The presence of cholesterol in membranes appears to be a critical determinant of the susceptibility of cells to these toxins and free cholesterol is a potent inhibitor of cytolytic activity (Smyth & Duncan, 1978). The generally accepted mode of cytolytic action involves the binding of monomeric toxin to mammalian cells via an interaction with cholesterol and the temperature-dependent insertion of the protein into the lipid bilayer. Aggregation of membrane-fixed toxin results in the generation of cholesterol-free toxin oligomers containing up to 80 monomers. These are thought to correspond to the ring and arc structures seen in treated cell membranes, which correlate with the appearance of transmembrane pores some 30–35 nm in diameter.

As well as causing cytolysis of mammalian cells, some thiol-activated toxins are cytotoxic to phagocytes and cells of the human immune system at concentrations (2 ng ml⁻¹) which have no effect on cell viability (Ferrante et al., 1984; Paton & Ferrante, 1983; Van Epps & Andersen, 1974). Pneumolysin inhibits neutrophil bactericidal activity (Paton & Ferrante, 1983) (by reducing chemotaxis, phagocytosis and the respiratory burst) and inhibits lymphocyte proliferation in response to mitogens and the synthesis of all immunoglobulin classes (Ferrante et al., 1984). These aspects of host defence are known to be important in protection against pneumococcal disease.

Although thiol-activated toxins are generally considered to be hydrophobic proteins (Johnson et al., 1982), the predicted sequences of five members of this toxin
family [pneumolysin, streptolysin O (SLO), listeriolysin, perfringolysin and alveolysin] that are available contain no extended stretches of hydrophobicity (Geoffroy et al., 1990; Kehoe et al., 1987; Kehoe & Timmis, 1984; Mengaud et al., 1988; Tweten, 1988; Walker et al., 1987). Thus the hydrophobic faces of these molecules which interact with membranes may be generated by the conformation they adopt in the membrane. The sequence of pneumolysin (Walker et al., 1987) lacks an N-terminal signal sequence, consistent with the reported cytoplasmic location of the protein in the pneumococcus (Johnson, 1977). The thiol-activated toxins show serological cross-reactivity (Smyth & Duncan, 1978) and there is extensive primary amino acid sequence homology between them (Geoffroy et al., 1990; Kehoe et al., 1987; Mengaud et al., 1988; Tweten, 1988; Walker et al., 1987).

The formation and breakage of intra-molecular disulphide bonds was previously thought to be the basis of the observed thiol activation, an hypothesis which implied that each toxin monomer contained at least two cysteine residues. Amino acid composition analysis of several thiol-activated toxins yielded varying estimates for their cysteine content (Geoffroy et al., 1981; Smyth & Duncan, 1978). However, for each of the toxins sequenced only one cysteine residue per monomer was found and this lies towards the C-terminus of the proteins in a conserved eleven-amino-acid sequence (-ECTGLAWEWWR-). This is inconsistent with thiol activation involving the formation and breakage of intramolecular disulphide bridges (Alouf, 1980; Smyth & Duncan, 1978).

The findings that oxidized toxin was not cytolytic and had lost the ability to bind to cells, and that SLO and alveolysin when treated with thiol-blocking agents lost cytolytic activity, suggested a critical role for a single thiol group in membrane-damaging activity (Alouf, 1980; Bhakdi & Tranum-Jensen, 1988; Geoffroy et al., 1981; Smyth & Duncan, 1978). This essential thiol group was postulated to have a role in cholesterol binding, direct induction of membrane damage or maintenance of an active conformation (Alouf, 1980; Bhakdi & Tranum-Jensen, 1988; Smyth & Duncan, 1978). The role of the unique cysteine in pneumolysin was probed using site-directed mutagenesis to change the single cysteine to alanine and, surprisingly, the modified toxin retained full cytolytic and cytotoxic activity (Saunders et al., 1990). Similar observations have been made with SLO (Pinkney et al., 1989) and listeriolysin (Michel et al., 1990). Thus there is no obvious role for the thiol group in the in vitro activity of pneumolysin, although it remains possible that the thiol group is important in vivo. For example, it may stabilize the toxins in vivo by promoting an interaction with other thiol-containing proteins.

Site-directed mutagenesis studies have revealed that the cysteine-containing motif is important for cytolytic and cytotoxic activity. When the unique cysteine in pneumolysin was changed to either serine or glycine, the cytolytic activity of the toxin was reduced, but not abolished (Saunders et al., 1990). The reduced activity of these toxins could not be wholly attributed to a defect in cell binding or an inability to form membrane-associated oligomers (Saunders et al., 1990). A similar result was obtained when tryptophans at positions 433 and 435 in pneumolysin were changed independently to phenylalanine (Boulnois et al., 1990). Similar findings were made with SLO (Pinkney et al., 1989) and listeriolysin (Michel et al., 1990). Thus the cysteine-containing motif appears to participate in the generation of the functional lesion in toxin-treated membranes after binding and oligomerization. We have recently observed that many of these modified pneumolysin molecules had a reduced, but still detectable, capacity to promote leakage of phosphorylcholine from mammalian cells (C. Pasternak and others, unpublished data), pointing to a role for the cysteine-containing motif in pore formation. In addition, these mutant toxins were found to have a reduced susceptibility to cation inhibition compared with the wild-type toxin (C. Pasternak and others, unpublished data).

Despite the conservation of the cysteine-containing motif, specific residues are not required for activity, suggesting that the overall structure of the motif is important. We postulated that this sequence motif promotes an interaction with cholesterol that is required for pore formation. We suggested this on the basis that a similar group of tryptophan residues is found in cholesterol oxidase (Boulnois et al., 1990). Additionally, tryptophan residues towards the C-terminus of the channel-forming polypeptide antibiotic gramicidin A are thought to play an essential role in channel formation by promoting an interaction with the ring structures of the sterol to orientate the polypeptide in the membrane so that hydrophilic domains span the membrane resulting in the pore formation (de Kruijff, 1990). This sequence of events may also apply to pneumolysin and the other thiol-activated toxins (de Kruijff, 1990).

Treatment of pneumolysin with the histidine-modifying agent diethyl pyrocarbonate (DEPC) abolished cytolytic activity and prevented toxin binding to cells (Boulnois et al., 1990; T. J. Mitchell and others, unpublished data). Only one conserved histidine (His156 in pneumolysin) is present in each of the toxins for which a predicted sequence is available and this residue was changed to arginine in pneumolysin. The modified toxin had only residual cytolytic activity but was shown to bind to cells normally yet was unable to form oligomers in membranes (Boulnois et al., 1990; T. J. Mitchell and others, unpublished data). Thus His156 in pneumolysin is involved in promoting either toxin-toxin or toxin-
membrane interactions required for oligomer formation. Histidine residues have also been implicated in the pentamerization or hexamerization of the toxin aerolysin (Green & Buckley, 1990). Interactions between cholesterol and the thiol-activated toxins are also thought to be important in oligomerization (Smyth & Duncan, 1978). The formation of functional pneumolysin oligomers may involve the cooperative action of His356, and the cysteine-containing motif.

The mechanism involved in the binding of toxin to mammalian cells is not understood, although in most models cholesterol is assumed to act as receptor (Alouf, 1980; Bhakdi & Tranum-Jensen, 1988; Smyth & Duncan, 1978). However, the evidence for this is only circumstantial and the relative inaccessibility of cholesterol within the membrane (Yeagle, 1987) may indicate a receptor distinct from the sterol. Toxin binding to cholesterol in cell membranes was proposed to involve a discrete region in the protein, the fixation site, since neutralizing antibodies which blocked SLO binding had no effect on activity of toxin pre-bound to cells (Alouf, 1980). Membrane binding has been postulated also to involve a hydrophobic interaction between toxin and sterol, or hydrogen bonding between several amino acids in the toxin and the 3β-OH groups of cholesterol (Alouf, 1980; Smyth & Duncan, 1978). The work discussed above suggests that toxin–receptor interactions do not involve the cysteine motif. In agreement with this notion, an N-terminal fragment of listeriolysin, lacking the cysteine-containing motif, bound to free cholesterol (Vazquez-Boland et al., 1989). In contrast, the cysteine in perfringolysin was proposed to mediate both receptor binding and membrane damage (Iwamoto et al., 1987). These apparently conflicting conclusions may indicate that free and membrane-associated cholesterol interact with different regions of the toxins. Alternatively, these conflicting views may reflect experimental difficulties associated with the use of cholesterol in aqueous solution.

Pneumolysin can activate the classical pathway of complement in the absence of anti-toxin antibodies (Paton et al., 1984). This may be of some consequence since complement is an important component of host defence against the pneumococcus (Winkelstein, 1982, 1984). In the fluid phase the ability of pneumolysin to activate complement may divert complement from the invading pneumococci and hence compromise complement-mediated opsonophagocytosis. If activation occurs on membrane-fixed toxin, as has been shown for SLO (Bhakdi & Tranum-Jensen, 1985), then this may result in the assembly of the membrane attack complex of complement on autologous membranes, which may contribute to tissue damage. Both scenarios would be expected to stimulate inflammatory responses (Bhakdi & Tranum-Jensen, 1985).

During the development of a pneumolysin-based ELISA, we observed a non-immune reaction between pneumolysin and antibody (Boulnois et al., 1990, 1991a; Mitchell et al., 1991). We subsequently demonstrated that intact antibody and purified Fc (but not Fab) fragments of antibody were bound by the toxin. Thus pneumolysin is another example of a bacterial protein with Fc-binding capacity. However we were unable to detect sequence homology between pneumolysin and other Fc-binding proteins. Pneumolysin lacks the antibody-binding repeat sequences that are typical of other Fc-binding proteins. However, it seemed reasonable to suppose that antibody binding and complement activation by pneumolysin might be related.

A clue to the domains of pneumolysin involved in complement activation was obtained when we observed that pneumolysin (and other thiol-activated toxins) has limited sequence homology with human CRP (Boulnois et al., 1990, 1991b; Mitchell et al., 1990b, 1991). A C-terminal sequence within CRP has homology with two non-contiguous segments in pneumolysin. CRP activates the classical pathway of complement in the absence of antibody via direct binding of the C1q component of complement to ligand-fixed CRP (Volanakis & Kaplan, 1974). It was thus intriguing that this bacterial protein toxin and human CRP share homology.

Site-directed mutagenesis of both CRP-like regions of pneumolysin has been carried out (Boulnois et al., 1990, 1991b; Mitchell et al., 1990b, 1991). Of the changes made in region 1 of pneumolysin (Phe263 to Trp, Glu264 to Gln, Gln277 to Gin and Trp278 to Phe), none affected complement activation or antibody binding. In contrast, changes in region 2 (Trp279 to Phe, Tyr284 to Phe, Asp285 to Asn and Trp297 to Phe) reduced both properties. The Tyr284 to Phe and the Asp285 to Asn modified toxins had only background ability to activate complement and an antibody-binding capacity reduced by about 70%. Thus we postulated that complement activation and antibody binding are interrelated and that non-immune binding of antibody contributes to classical pathway activation (Boulnois et al., 1990, 1991a; Mitchell et al., 1990b, 1991). Whether or not the homologous sequence in CRP also promotes antibody binding is not known but CRP-mediated complement activation requires only C1q. A preliminary experiment revealed that pneumolysin also can bind C1q directly, although changes made in the CRP-like region 2 of pneumolysin had no effect on C1q binding (T. J. Mitchell and others, unpublished data); however, it remains possible that CRP-like region 1 of pneumolysin is involved in C1q binding. Whether or not C1q binding by pneumolysin contributes to classical pathway activation is not known.

The mechanisms by which pneumolysin binds antibody via Fc and activates complement is not clear,
although Tyr384 and Asp385 appear to be important. A
tyrosine–acidic amino acid pair is also found in the IgG-
binding domains of proteins A and G and, in the former,
the tyrosine residue is known to interact with antibody
(Fahnestock et al., 1990; Guss et al., 1990). More than
one molecule of IgG in close proximity is normally
required to activate the classical pathway of complement
(Wright et al., 1980). This might be achieved indirectly
by pneumolysin as a consequence of its tendency to
aggregate in solution, such that monovalent binding
of antibody by pneumolysin would suffice to activate
complement. Alternatively, pneumolysin might have
more than one antibody-binding site, and it is interesting
that the Asp385 to Asn modified pneumolysin retains
some capacity to bind antibody despite being unable to
activate complement. Other models for complement
activation by pneumolysin require that C1q binding by
the toxin contributes to activation. For example, the
globular heads of C1q might bind directly to the toxin
and the Fc domain of antibody bound to CRP-like region
2. Alternatively, the Fc domain of a single antibody
might bring two molecules of toxin, and hence two C1q
binding sites, into close apposition.

Whether or not complement activation by pneumolysin
is important in vivo during normal infection with the
pneumococcus is not known. Pneumolysin might act as a
CRP analogue but without the appropriate ligand-
binding properties. In this way pneumolysin might
compete with CRP and abrogate its protective effect.
Purified recombinant pneumolysin, when injected into
the ligated lobe of a rat lung, causes the same histological
features of lobar pneumonia as does inoculation of
similar lobes with virulent pneumococci (Feldman et al.,
1991). Administration of modified pneumolysin defec-
tive in either membrane-damaging capacity or comple-
ment activation caused less inflammation, providing
evidence that pneumolysin-mediated complement activ-
tion can occur in vivo and thus has the potential to
contribute to disease. Pneumolysin may act in conjunc-
tion with cell wall components (Tuomanen et al., 1987) to
induce inflammation in the lung.

Autolysin and the release of pneumococcal
virulence factors

It is clear that a number of pneumococcal factors are
potentially important in the pathogenesis of disease.
However, in the case of pneumolysin (Johnson, 1977)
and perhaps neuraminidase (Lock et al., 1988), these
factors appear to be located in the cytoplasm of the
pneumococcus. Both of these proteins are released from
the cell during autolysis, a process mediated by the cell-
wall-associated autolysin. Interestingly, a defined autoly-
sin-negative mutant of the pneumococcus had reduced
virulence in mice following intranasal challenge and
immunization of mice with autolysin conferred limited
protection against intranasal challenge with wild-type
pneumococci (Berry et al., 1989a). Thus autolysin
contributes to virulence, although this may be indirect,
with the enzyme releasing proteins and cell wall
fragments which can contribute to virulence and inflam-

An improved pneumococcal vaccine?

The above discussion serves to highlight the potential
importance of pneumolysin in the pathogenesis of
disease, and the ability of the toxin to confer limited
protection upon mice in a serotype-independent manner
has been described (Paton et al., 1983, 1991). The current
pneumococcal vaccine, comprising 23 polysaccharides
from the most frequently encountered pneumococcal
serotypes, has significant shortcomings. These relate
primarily to the poor immunogenicity of capsular
polysaccharides but many studies have shown that
immunogenicity and memory to polysaccharide antigens
can be achieved by the conjugation of the polymer to a
protein carrier. Pneumolysin may be the ideal carrier for
the pneumococcal polysaccharide vaccine since im-
proved immunogenicity may accompany induction of
anti-toxin antibodies which themselves may be protec-
tive in a serotype-independent way. The genetically
toxoided pneumolysin molecules described above would
be ideal for this purpose since they have dramatically
reduced biological activities. We have recently reported
the purification and immunogenicity of the toxoided
derivatives of pneumolysin to the type 19F polysacchar-
ide (Paton et al., 1991). The 19F polysaccharide was
chosen because it is a particularly poor immunogen in
children and mice. The conjugation was found to convert
the 19F polymer into an antigen capable of inducing a
booster effect and it seems likely that coupling the 19F
polysaccharide to pneumolysin converted it into a T-cell-
dependent antigen. The conjugate also gave modest
responses to pneumolysin and it will be interesting to
assess if any protection afforded is serotype independent.

This work was supported in part by grants from the MRC and the
Wellcome Trust. G.J.B. is a Lister-Jenner Fellow. I am indebted to
many collaborators (Dr J. Paton, Dr R. Wilson, Dr F. Mendez,
Professor C. Pasternak, Dr L. Bashford) who made this work possible.
I am particularly pleased to thank my colleagues, Dr Peter Andrew and
Dr Tim Mitchell, of the Microbiology Department at Leicester, for
their longstanding collaboration and help in ways too numerous to
mention. A number of PhD students (J. Walker, S. Pratt, A. Shepherd,
K. Saunders, J. Canvin, R. Owen and M. Camara-Garcia) have also
played a central role in these studies.
References


The induction of meningeal inflammation by components of the pneumococcal cell wall. 

American Review of Respiratory Disease 136, 259-261.


